Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA

TipRanks01-08

BofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps a Neutral rating on the shares. While political and rate uncertainty continues...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501226367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 20:26","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501226367","market":"us","top_or_hot":-1,"title":"Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA","media":"TipRanks","content":"<div>\n<p>BofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps a Neutral rating on the shares. While political and rate uncertainty continues...</p>\n\n<a href=\"https://finance.yahoo.com/news/recursion-pharmaceuticals-price-target-lowered-122602936.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecursion Pharmaceuticals price target lowered to $10 from $12 at BofA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 20:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/recursion-pharmaceuticals-price-target-lowered-122602936.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps a Neutral rating on the shares. While political and rate uncertainty continues...</p>\n\n<a href=\"https://finance.yahoo.com/news/recursion-pharmaceuticals-price-target-lowered-122602936.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-price-target-lowered-122602936.html","article_id":"2501226367","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-price-target-lowered-122602936.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501226367","pubTimestamp":1736339162,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"BofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals  to $10 from $12 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investor focus,” the analyst tells investors in a sector outlook note.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia. Recursion Pharmaceuticals call volume above normal and directionally bullish. Recursion Pharmaceuticals’  Bold Acquisition Places it as an Industry Leader. Recursion anno","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"美国银行将Recursion Pharmaceuticals目标价从12美元下调至10美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"BofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investor focus,” the analyst tells investors in a sector outlook note.\n\nStay Ahead of the Market:\n\nDiscover outperforming stocks and invest smarter with Top Smart Score Stocks\nFilter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee Insiders’ Hot Stocks on TipRanks >> \n\n\nRead More on RXRX:\n\nRecursion Pharmaceuticals CFO Ben Taylor to Join Exscientia\nRecursion Pharmaceuticals call volume above normal and directionally bullish\nRecursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader\nRecursion announces first patient dosed in Phase 1/2 trial of REC-1245\nUnusually active option classes on open December 2nd","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"rating","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501226367"}